Profil bibliographique

Ivan D. Horak

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

458Publications signalées
17680Citations signalées
0Affiliations récentes

Les domaines associés

CAR-T cell therapy researchMonoclonal and Polyclonal Antibodies ResearchImmune Cell Function and InteractionHER2/EGFR in Cancer ResearchImmunotherapy and Immune Responses

Les publications récentes

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S12 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Pei Y. Teo, Youngrock Jung, David H. Quach, Joanna Koh et autres

Supplementary Figure S12. Allogeneic rejection of ‘donor’ CD30.CAR with 4-1BB spacer (CD30.bb) EBVSTs occurs with the administration of alloreactive ‘recipient’ Allo-T cells in a CD30-positive B-cell acute lymphoblastic leukemia (B-ALL) mouse model. A, Schematic of in-vivo B-ALL allorejection model for (B-D), in …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S2 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Pei Y. Teo, Youngrock Jung, David H. Quach, Joanna Koh et autres

Supplementary Figure S2. Mixed lymphocyte reaction assay with TCRαβKO ATCs. A, Expression of TCRαβ on CD3 wild-type (WT) T cells or T cells after TCRαβKO gene modification using Crispr gene editing measured by flow cytometry analysis. B, Expression of different variants of …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S1 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Pei Y. Teo, Youngrock Jung, David H. Quach, Joanna Koh et autres

Supplementary Figure S1. Gating strategies employed in the study. Sample gating strategy for in vitro MLR assay using PBMCs as “recipient” cells (A) or Allo-T cells as ‘recipient’ cells (B). C, Sample gating strategy for the expression of intracellular or surface markers …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S16 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Pei Y. Teo, Youngrock Jung, David H. Quach, Joanna Koh et autres

Supplementary Figure S16. Effects of SB9 overexpression on the exhaustion status of CD30.CAR with 4-1BB spacer (CD30.bb) or CD19.CAR TCRαβKO ATCs following sequential encounters with tumor cells as described in Fig. 5A. Effector CAR T cells were co-cultured with HLADKO NALM6-CD30 tumor …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S14 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Pei Y. Teo, Youngrock Jung, David H. Quach, Joanna Koh et autres

Supplementary Figure S14. Overexpression of SB9(CAS) in ‘donor’ CD30.CAR with 4-1BB spacer (CD30.bb) EBVSTs increases resistance to allorejection in a B-ALL allorejection model in which ‘donor’ CAR T cell and ‘recipient’ cell levels were quantified via IVIS imaging and flow cytometry, respectively. …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S8 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Pei Y. Teo, Youngrock Jung, David H. Quach, Joanna Koh et autres

Supplementary Figure S8. Overexpression of SB9(CAS) in ‘donor’ CD30.CAR with IgG1 spacer (CD30.Ig) TCRαβKO ATCs increases resistance to allorejection by ‘recipient’ Allo-T cells. A, Schematic of in-vitro MLR co-culture setup for (B-E), where ‘donor’ CD30.Ig TCRαβKO ATCs and ‘recipient’ Allo-T cells, which …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S15 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Pei Y. Teo, Youngrock Jung, David H. Quach, Joanna Koh et autres

Supplementary Figure S15. Allogeneic rejection of ‘donor’ CD30.CAR with 4-1BB spacer (CD30.bb) EBVSTs occurs in mice engrafted with HLA-mismatched ‘recipient’ PBMCs in a cutaneous T cell lymphoma (CTCL) allorejection model. A, CD30, HLA-ABC and HLA-DRDPDQ expression on wildtype (WT) compared to human …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S4 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Pei Y. Teo, Youngrock Jung, David H. Quach, Joanna Koh et autres

Supplementary Figure S4. CD30.CAR with 4-1BB spacer (CD30.bb) EBVSTs expressing different forms of SB9 had similar CD30.bb expression and T cell characteristics. (A, left) SDS-PAGE analysis of SB9 expression from a representative donor, where the top band (∼62 kDa) indicates the pre-formed …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S3 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Pei Y. Teo, Youngrock Jung, David H. Quach, Joanna Koh et autres

Supplementary Figure S3. CD30.CAR with IgG1 spacer (CD30.Ig) TCRαβKO ATCs expressing different variants of SB9 had similar CD30.Ig expression and cytotoxicity. A, Expression of TCRαβ on CD3 wildtype (WT) T cells or T cells after TCRαβKO gene modification using Crispr gene editing …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S6 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Pei Y. Teo, Youngrock Jung, David H. Quach, Joanna Koh et autres

Supplementary Figure S6. Overexpression of SB9(CAS) in ‘donor’ CD30.CAR with IgG1 spacer (CD30.Ig) EBVSTs increases resistance against allorejection by HLA-mismatched CD30-intact ‘recipient’ PBMCs. A, CD30.Ig expression on EBVSTs expressing different variants of SB9, measured by flow cytometry analysis of a representative donor. …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S7 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Pei Y. Teo, Youngrock Jung, David H. Quach, Joanna Koh et autres

Supplementary Figure S7. Manufacturing of Allo-T cells which are pre-primed alloreactive ‘recipient’ cells that recognize and kill ‘donor’ cells. A, Manufacturing timeline for the generation of Allo-T. B, CD30 expression of CD30KO Allo-T cells determined by the staining of CD30 with two …

0 citations
Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S17 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Pei Y. Teo, Youngrock Jung, David H. Quach, Joanna Koh et autres

Supplementary Figure S17. CD30-positive B-cell acute lymphoblastic leukemia (B-ALL) burden of two in-vivo models that were being used to test SB9-mediated protection of ‘donor’ cells against allorejection (allorejection model) and AICD (AICD model), respectively. Bioluminescence signals from HLADKO NALM6-CD30.eGFP-ffLuc that were prepared …

0 citations
Profil ORCIDNotice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.